RxDoctor Payments Data

Sherryl Ashberg, MD

Family Medicine · Jupiter, FLNPI 1104827229

Payments from drug & device makers

$2,447in general payments, 2019–2025

Across 85 payments — averaging $28.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$803
  • AbbVie$335
  • Amgen$261
  • Lilly USA, LLC$250
  • Pfizer$197
  • Stryker$164
  • plus $437 from 12 others

What the payments were for

  • Consulting fees$90%
  • Food & beverage$2,438100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,447 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$121,287
Medicare patients
344
Services billed
1,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$75,615
MounjaroTirzepatide53$55,411
EliquisApixaban37$38,549
JardianceEmpagliflozin21$28,897
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$25,085
ProliaDenosumab14$24,279
XareltoRivaroxaban21$15,762
MyrbetriqMirabegron11$12,859
PremarinEstrogens, Conjugated19$5,914
Lisdexamfetamine Dimesylate13$3,933
SynthroidLevothyroxine Sodium46$3,170
Atorvastatin Calcium407$3,019
Rosuvastatin Calcium284$2,056
Levothyroxine Sodium249$1,917
Losartan Potassium249$1,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$803$75,61561 claims
Lilly USA, LLCMounjaro$250$55,41153 claims
PfizerEliquis, Premarin$197$44,46356 claims
Boehringer IngelheimJardiance$20$28,89721 claims
GSKTrelegy Ellipta$30$25,08516 claims
AmgenProlia$261$24,27914 claims
Johnson & JohnsonXarelto$30$15,76221 claims
AbbVieSynthroid$335$3,17046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →